BioSpace News Archive

BerGenBio today announced the presentation of data from its broad phase II clinical development programme with its selective AXL inhibitor bemcentinib in two posters at the ASCO-ITC Clinical Immuno-Oncology Symposium.

The Pall Biotech business unit has been named to reflect an important strategic direction for the company.

Studies over the past decade have demonstrated that there is a dynamic interaction between a patient’s immune system and the existence of a tumor.

Otsuka announce that the latter has been awarded a grant for up to US $10 million from the Bill & Melinda Gates Foundation to advance clinical development of Otsuka’s investigational compound to treat tuberculosis (TB), OPC-167832, in combination with delamanid as the backbone of a pan-TB regimen in line with the World Health Organization’s (WHO) Target Regimen Profiles (TRP).

BioTime, Inc. today announced that detailed data from the successful pivotal trial of Renevia in Europe will be presented at the International Master Course on Aging Science (IMCAS) conference on February 3, 2018.

ESCADA reports a prospective, randomized, controlled, multi-center trial comparing decompression alone to decompression with coflex Interlaminar Stabilization for treatment of moderate to severe lumbar spinal stenosis.

Auberton-Herve will replace Peter Bloch, who has resigned from his role as Chairman of the Board, effective January 24, 2018. Bloch will remain as a Director.

A 30-year veteran of Johnson & Johnson’s Research & Development division, Madden has unparalleled experience in bringing exceptional new products and technologies to the market.

Upon its launch, which is targeted to be April 2, 2018, FIRVANQ will replace CutisPharma’s FIRST-Vancomycin Unit-of-Use Compounding Kit.

As part of the program introduction, Dr. Verma and NFL broadcaster Solomon Wilcots will discuss the medical need and opportunity for the CTE vaccine program with journalists Jan. 30-31 on Super Bowl Radio Row in Minneapolis.